PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Besilesomab→

Besilesomab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
537694-98-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Murine monoclonal anti-NCA-95 antibodydiagnostic radiopharmaceutical precursor (99mTc-labelled kit)
Mechanism of action
Binds the NCA-95 antigen on granulocytes. Following radiolabelling with technetium-99m, the antibody carries radioactivity to granulocyte-rich sites of infection or inflammation, allowing scintigraphic localisation.
Indications / reported uses
  • Diagnostic scintigraphic imaging, alongside other appropriate imaging modalities, to locate peripheral bone infection/inflammation in adults with suspected osteomyelitis; not for diagnosing diabetic-foot infection

Sources: EMA EPAR — Scintimun · EMA product information (updated 9 Jun 2026) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Besilesomab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Besilesomab Permitted Daily Exposure (PDE) report (the Besilesomab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Besilesomab Occupational Exposure Limit (OEL) report (the Besilesomab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.